Skip to main navigation
Skip to search
Skip to main content
Fox Chase Cancer Center Home
Help & FAQ
Home
Profiles
Research Units
Research Resources
Research Outputs
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
The two faces of interferon-γ in cancer
M. Raza Zaidi
, Glenn Merlino
Center for Immunology
Cancer Signaling and Microenvironment (CSM)
National Institutes of Health
Research output
:
Contribution to journal
›
Review article
›
peer-review
493
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The two faces of interferon-γ in cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Malignant Neoplasm
100%
Cancer
100%
Interferon
100%
Therapeutic Procedure
50%
Combination Therapy
50%
Cells
50%
Neoplasm
50%
Receptor
50%
Cytokine
50%
Adaptive Immunity
50%
Biological Activity
50%
Immunosurveillance
50%
Side Effect
50%
Cytostatic Agent
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Interferon
100%
Receptor
50%
Neoplasm
50%
Cytokine
50%
Side Effect
50%
Biological Activity
50%
Cytostatic Agent
50%
Immunology and Microbiology
Interferon Type I
100%
Cells
50%
Cytokine
50%
Flow
50%
Adaptive Immune System
50%
Immunosurveillance
50%
Biological Activity
50%